TY  - JOUR
T1  - Pharmacogenetic Insights into Glucagon-Like Peptide-1 Receptor and Its Role in Diabetes Therapy
A1  - Chloe Davis
A1  - Liam Taylor
A1  - Isabella Moore
JF  - Annals of Pharmacy Practice and Pharmacotherapy
JO  - Ann Pharm Pract Pharmacother
SN  - 3062-4436
Y1  - 2023
VL  - 3
IS  - 1
DO  - 10.51847/QbAABZN70k
SP  - 145
EP  - 154
N2  - Type 2 diabetes mellitus (T2DM) represents a multifactorial metabolic disorder primarily marked by impaired insulin secretion and the presence of insulin resistance. If left untreated, T2DM inevitably progresses to various long-term complications. The emergence of novel therapeutic agents, such as Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs), has introduced new possibilities for improved glycemic regulation and additional metabolic advantages. Pharmacogenetics, a branch of pharmacotherapy, explores how genetic polymorphisms influence individual responses to specific medications. This review focuses on the current scientific understanding of the pharmacogenetics of GLP-1 receptor agonists—particularly liraglutide—and their potential role in the personalized management of T2DM.
UR  - https://galaxypub.co/article/pharmacogenetic-insights-into-glucagon-like-peptide-1-receptor-and-its-role-in-diabetes-therapy-7ml68zfy3zoxorq
ER  -